Piyasa kapalı· · CNY · Veriler gecikmeli olabilir
Fiyatlar gecikmeli olabilir ve yalnızca bilgilendirme amaçlıdır - yatırım tavsiyesi değildir.
Temettüler dahil toplam getiri.
Fiyatın 50 ve 200 günlük hareketli ortalamalara göre konumu.
Makkler Adil Değer, finansal sağlık skoru, analist görüşü, benzer şirketler ve MakklerAI.
Lilly wagered up to $3.35 billion in its fourth China-focused alliance since January 2025. Elsewhere, analysts are now more confident about one of Vertex’s top prospects and an RNA drug succeeded against a rare form of ALS.
Phase 2b dose ranging data presented at ERS show both doses of AN01 delivered significant and clinically relevant improvements in lung function versus placebo at Week 4Trial comprised of broad COPD population, including participants on background single or dual bronchodilator therapy AN01 was well tolerated with no treatment-related adverse events reported in the 0.75 mg dose group, the dose under investigation in the Phase 3 program AirNexis has completed its Phase 1 multiple ascending dose (MA
On August 25, Haisco Pharmaceutical Group Co., Ltd. ("Haisco") (Ticker Code: 002653) announced that it has entered into an exclusive licensing agreement with Sentivera, a new US venture founded by Population Health Partners ("PHP") and ARCH Venture Partners ("ARCH"), to grant Sentivera the rights to develop, manufacture, and commercialize its independently developed one pre-clinical innovative drug globally, excluding Greater China.
Üçüncü taraf yayıncıların bu şirket hakkındaki son başlıkları; Makkler'in kendi editoryal içeriğinden ayrı tutulur ve dış kaynağa yönlendirir. Başlıkların doğruluğu ilgili yayıncının sorumluluğundadır.